ProteinQure Inc.
25.3.2024 05:03:30 CET | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models. The experiments were conducted in the lab of Dr. David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world's top five cancer research centres.
Developed through ProteinQure's cutting-edge computational platform, the innovative SORT1 targeting PDC is a novel peptide attached to a highly potent chemotherapeutic agent. The drug candidate was tested across a broad range of breast cancer models. The results demonstrated remarkable antitumor efficacy, including cancers resistant to standard chemotherapies and antibody-drug conjugates.
"Working with the David Cescon Lab at UHN has been instrumental in validating our novel PDC's efficacy against one of the most challenging forms of breast cancer. Based on these results, we are moving our lead program forward into IND-Enabling studies and our first clinical trial," said Lucas Siow, CEO of ProteinQure. "These findings not only highlight the power of our computational drug design platform but also represent significant validation in our quest to develop tissue-specific peptides for targeted drug delivery."
ProteinQure's collaborators will present the data at the upcoming American Association for Cancer Research (AACR) conference in San Diego. The AACR conference, renowned for showcasing the latest innovations in cancer research, provides the perfect stage to share these findings with the global cancer research community.
"We are excited to present this data at AACR and help develop new therapeutic options for breast cancer, especially with promising Canadian startups," stated Dr. David Cescon, head of the lab at UHN. "The success of this unique PDC in diverse PDX models is a testament to the potential of combining advanced computational techniques, precision oncology, and our labs' robust preclinical platform".
Funding for parts of this work included contributions from IRAP-Canada and the INOVAIT program based out of Sunnybrook Hospital.
Poster Presentation Details:
Title: In-vivo efficacy of a novel peptide-conjugated drug in patient-derived xenograft models of breast cancer
Session Title: New Targets
Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET
Abstract Number: 5911
Speaker: Mitchell Elliott, UHN Princess Margaret Cancer Centre
About ProteinQure
ProteinQure is a pioneering startup specializing in the computational design of peptide drugs utilizing state-of-the-art artificial intelligence and molecular simulation technologies. With a focus on precision medicine, ProteinQure is dedicated to transforming the landscape of drug development and ushering in a new era of targeted effective treatments.
About the David Cescon Lab at UHN
The David Cescon Lab at the University Health Network is a leader in breast cancer research, focusing on the mechanisms of cancer progression and resistance to therapy. Through cutting-edge pre-clinical and clinical research and collaborations, the lab develops novel therapeutic strategies aimed at improving outcomes for cancer patients worldwide.
For further information, please contact:
Lucas Siow - CEO of ProteinQure - press@proteinqure.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
SOURCE: ProteinQure Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution17.3.2026 15:05:00 CET | Press release
Redshift for Vectorworks now available, Autodesk Revit® beta open for sign-ups, and Graphisoft Archicad releasing later in 2026. Maxon unveils a deeper look at its end-to-end 3D workflow for architects and designers in 2026 and beyond. BAD HOMBURG, DE / ACCESS Newswire / March 17, 2026 / Maxon, maker of powerful, approachable software solutions for creators working in 2D and 3D design, motion graphics, visual effects, gaming, and more, today announced the commercial availability of Redshift for Vectorworks. Additionally, the company announced the beta launch of Redshift for Autodesk Revit®. This marks the next major milestone in Maxon's expansion into the Architecture, Engineering & Construction (AEC) market, with additional integrations planned. Engineered for architects and interior designers, Maxon's AEC solution brings the company's industry-proven cinematic rendering technology, Redshift, and the creative depth of Cinema 4D directly into professional archviz workflows. Designed as
Sauce Labs CEO, Prince Kohli, Says $1 Trillion Software Quality Industry Has Been "Building Wrong" for 20 Years17.3.2026 15:00:00 CET | Press release
The new Sauce AI for Test Authoring launch targets the most labor-intensive slice of the 22% of IT budgets spent on quality assurance, by shifting engineering teams from writing test cases to specifying business intent that the platform autonomously turns into self-improving test suites. SAN FRANCISCO, CA / ACCESS Newswire / March 17, 2026 / Sauce Labs Inc., the world's largest full-lifecycle, test automation platform, today announced the general availability of Sauce AI for Test Authoring, an AI Agent that translates business intent into framework-agnostic executable test suites that can be run instantly on Sauce Labs' virtual and real-device clouds. This launch introduces a new paradigm for DevOps: Intent-Driven Testing, designed to bridge the "Velocity and Quality Gap", the widening distance between how fast AI generates code and how slowly teams can validate it for enterprise-grade quality. High-quality test creation is one of software development's most persistent bottlenecks. Dev
Datavault AI Schedules Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 202617.3.2026 12:00:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / March 17, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, today announced that it will report financial results for its fourth quarter and full year 2025 prior to market open on Thursday, March 19, 2026. Following the release, Datavault AI will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET. Conference Call and Webcast Information Date: Thursday, March 19, 2026, at 8:30 a.m. ET Participant Dial-in (US): 1-877-405-1216 Participant Dial-in (International): 1-201-689-8336 Webcast Access: Click Here Datavault AI CEO, Nathaniel Bradley, and CFO Brett Moyer, will be presenting. A replay of the webcast will be made available later in the day in the Investors/Presentations section of the Datavault AI website: Click Here. About Datavault AI Inc. Datavault AI TM (NASDAQ:DVLT) is leading the
Ondas Completes Acquisition of Rotron Aerospace Ltd., Expanding Long-Range Propulsion Technologies for Advanced Unmanned Systems for Defense16.3.2026 13:30:00 CET | Press release
UK-Based Rotron Aerospace Strengthens Ondas' Systems of Systems Architecture with Unmanned Aircraft Platforms, Aero-Engine Technologies, and Long-Endurance Autonomous Mission Capabilities Expands Ondas' Strategic Footprint Within the UK and NATO Ecosystems, Providing Fast-Track Access to Major Programs Through Deep-Rooted Relationships with the UK Ministry of Defence Establishes a UK Industrial Base for Advanced Unmanned Systems Supporting NATO Programs and Allied Defense Localization Initiatives WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / March 16, 2026 / Ondas Inc. (Nasdaq:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous aerial and ground robot intelligence through its Ondas Autonomous Systems (OAS) business unit and private wireless solutions through Ondas Networks, today announced the completion of its acquisition of Rotron Aerospace Ltd. (Rotron), a UK-based developer of advanced unmanned aerial systems and long-range autonomous platforms designed for
Global Anti-Scam Alliance Launches Scam.org with OpenAI and Key Partners12.3.2026 11:00:00 CET | Press release
AI technology meets on-the-ground expertise from leading organizations across five continents, accessible to billions of consumers in 50+ languages covering 97% of global internet users. AMSTERDAM, NL / ACCESS Newswire / March 12, 2026 / The Global Anti-Scam Alliance (GASA) launched today Scam.org, an AI-powered platform that provides scam education, prevention, detection, reporting, and victim support in over 50 languages, making it a new global hub, accessible to 97% of the world's internet users. Scam.org is powered by partnerships with OpenAI and leading cybersecurity organizations, AnyTech365, CUBE AI,Falkin, Malwarebytes, Netcraft, ReasonLabs, ScamAdviser, Scamnetic, Seraph Secure and Spamhaus. For personal victim support, Scam.org collaborates with other victim support organizations such as AARPin the USA and ANVINT in Brazil. The platform expects more organizations to join, with plans to build an even stronger and broader coalition, creating a world where people are safer from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom